Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 10/20 | 0.58 |
| ▸ | FABP2 | P12104 | 1/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10970721 | 0.82 | PPARA (0.42) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL247466 | 0.81 | PPARA (0.68) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL7026339 | 0.79 | PPARA (0.66) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL8889149 | 0.79 | PPARA (0.66) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL7032523 | 0.79 | PPARA (0.66) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL11545612 | 0.79 | PPARA (0.71) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| Clofibric Acid SCHEMBL11798397 | 0.78 | PPARA (0.96) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL3844599 | 0.78 | PPARA (0.69) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| Methylamine SCHEMBL27865949 | 0.78 | PPARA (0.63) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL1045831 | 0.78 | PPARA (0.69) | PPARAMEN1KMT2ACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-7705023-B2 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2010-04-27 | — | — | US | disclosed |
| EP-1778632-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | PPARA 2456/4885MEN1 3587/4885KMT2A 3218/4885 |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | PTGS1, IDO1, PTGES | PPARA 1067/4885MEN1 3621/4885KMT2A 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.